Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin, Sintilimab, S-1 and Radiotherapy in Gastric Cancer
NCT06487429Phase 2Recruiting
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in gastric cancer (GC). Started May 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06487429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487429.